Normane Sharpless News Today

G1 Therapeutics, Inc. (NASDAQ:GTHX – Get Rating) was the target of a large decrease in short interest in May. As of May 31st, there was short interest totalling 2,960,000 shares, a decrease of 5.1% from the May 15th total of 3,120,000 shares. Based on an average trading volume of 886,800 shares, the days-to-cover ratio is […]

G1 Therapeutics, Inc. (NASDAQ:GTHX – Get Rating) has been given an average rating of “Moderate Buy” by the six analysts that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1 year target […]

G1 Therapeutics (NASDAQ:GTHX – Get Rating) and GlobeStar Therapeutics (OTCMKTS:GSTC – Get Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, risk and profitability. Institutional & Insider Ownership 53.1% of G1 Therapeutics shares […]

G1 Therapeutics, Inc. (NASDAQ:GTHX – Get Rating) was the recipient of a significant decrease in short interest during the month of April. As of April 30th, there was short interest totalling 3,310,000 shares, a decrease of 12.4% from the April 15th total of 3,780,000 shares. Based on an average daily trading volume, of 1,190,000 shares, […]

Shares of G1 Therapeutics, Inc. (NASDAQ:GTHX – Get Rating) have received an average recommendation of “Moderate Buy” from the six research firms that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12 month […]

G1 Therapeutics, Inc. (NASDAQ:GTHX – Get Rating) – Investment analysts at Wedbush upped their Q2 2023 EPS estimates for G1 Therapeutics in a research report issued to clients and investors on Wednesday, May 3rd. Wedbush analyst D. Nierengarten now forecasts that the company will earn ($0.51) per share for the quarter, up from their previous […]

G1 Therapeutics, Inc. (NASDAQ:GTHX – Get Rating) saw a large drop in short interest in April. As of April 15th, there was short interest totalling 3,780,000 shares, a drop of 10.2% from the March 31st total of 4,210,000 shares. Based on an average daily volume of 1,170,000 shares, the short-interest ratio is currently 3.2 days. […]

Needham & Company LLC reissued their buy rating on shares of G1 Therapeutics (NASDAQ:GTHX – Get Rating) in a research note published on Wednesday, Benzinga reports. They currently have a $18.00 price objective on the stock. GTHX has been the topic of several other research reports. JPMorgan Chase & Co. upgraded shares of G1 Therapeutics […]

Needham & Company LLC reaffirmed their buy rating on shares of G1 Therapeutics (NASDAQ:GTHX – Get Rating) in a research report sent to investors on Wednesday morning, Benzinga reports. Needham & Company LLC currently has a $18.00 price objective on the stock. Several other research analysts have also commented on the company. EF Hutton Acquisition […]

Shares of G1 Therapeutics, Inc. (NASDAQ:GTHX – Get Rating) have earned a consensus rating of “Moderate Buy” from the six ratings firms that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 1-year target […]